Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Amphastar Pharmaceuticals to post earnings of $0.03 per share for the quarter.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.07. The business had revenue of $79.79 million during the quarter, compared to analyst estimates of $76.21 million. Amphastar Pharmaceuticals had a net margin of 0.74% and a return on equity of 5.14%. The firm’s revenue for the quarter was up 36.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.05 earnings per share. On average, analysts expect Amphastar Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of AMPH traded up $0.22 during trading hours on Tuesday, reaching $19.58. 8,260 shares of the company traded hands, compared to its average volume of 145,887. The firm has a fifty day moving average of $20.26. The firm has a market cap of $935.19 million, a PE ratio of 93.19 and a beta of 1.35. The company has a current ratio of 2.06, a quick ratio of 1.35 and a debt-to-equity ratio of 0.11. Amphastar Pharmaceuticals has a 1-year low of $16.18 and a 1-year high of $25.43.
A number of brokerages have recently commented on AMPH. Wells Fargo & Co set a $29.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, June 6th. BidaskClub raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $24.64.
In related news, insider Jason B. Shandell sold 6,615 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $20.31, for a total value of $134,350.65. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 30.80% of the stock is currently owned by corporate insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Recommended Story: What is a CD ladder?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.